Speaker Detail

Jim Healy is managing general partner of Sofinnova. He has over 20 years of experience in biomedical research, development and finance. He specializes in financing late-stage drug development and pharmaceutical spinoffs. Healy invests in private equity and small-cap public financings, and serves or has served on the boards of companies in Belgium, Ireland, Switzerland and the United States. He currently serves on the boards of Amarin (AMRN), Anthera (ANTH), Durata (DRTX), Intermune (ITMN) and Sorbent. He has financed and been a board member of six companies that received either FDA or EMA approval to market their drugs. Healy graduated with a B.A. in molecular biology from the University of California, Berkeley. He received his M.D. and Ph.D. in immunology from the Stanford University School of Medicine through the NIH Medical Scientist Training Program. He also performed neuroscience research at the University of Virginia School of Medicine. Healy has authored or co-authored 13 peer-reviewed articles and invited reviews, including three papers published in Nature.